According to FutureWise analysis the market for bioresorbable stent in 2023 was US$ 0.99 billion, and is expected to reach US$ 1.97 billion by 2031 at a CAGR of 9%.

Bioresorbable stents, commonly referred to as bioresorbable scaffolds (BRS), represent a notable advancement in interventional cardiology. These innovative devices are engineered to provide temporary support to arteries that are narrowed or blocked, gradually dissolving in the body over time. This design eliminates the need for a permanent metallic implant, addressing one of the primary shortcomings associated with traditional metallic stents, whether bare-metal or drug-eluting.

Traditional stents have been the standard treatment for coronary artery disease (CAD), but they can lead to complications such as in-stent restenosis, late stent thrombosis, and potential interference with imaging or surgical interventions. Bioresorbable stents aim to resolve these issues.

Constructed from materials like polylactic acid (PLA) or magnesium alloys, bioresorbable stents effectively maintain vessel patency and deliver anti-proliferative drugs during the crucial initial healing phase after angioplasty. Once their function is fulfilled, these stents are absorbed by the body, typically within 2 to 3 years, which enables the artery to return to its natural state, including the restoration of vasomotion.

The benefits of bioresorbable stents include a lower risk of chronic inflammation, improved compatibility with future treatment options, and enhanced long-term vessel healing. However, early-generation BRS devices encountered challenges such as thicker struts, suboptimal mechanical characteristics, and higher thrombosis rates compared to traditional drug-eluting stents. Nonetheless, ongoing research and development efforts are yielding new generations of BRS with superior designs, thinner profiles, and improved safety and efficacy.

The market for bioresorbable stents is projected to experience significant growth, driven by the increasing prevalence of cardiovascular diseases, a global trend toward minimally invasive procedures, and advancements in biodegradable materials. As clinical outcomes continue to enhance and regulatory approvals expand, bioresorbable stents are likely to play a crucial role in transforming the landscape of both coronary and peripheral artery interventions.

FutureWise Market Research has published a report that provides an insightful analysis of Bioresorbable Stent Market trends that are affecting the overall market growth.



Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=4246&type=requestsample

Bioresorbable Stent Market Segmentation:

By Material

  • Bioresorbable polymer based stents
  • Bioresorbable metallic stents

By Absorption Rate

  • Slow- absorption stents
  • Fast- absorption stents

By Application

  • Coronary Artery Diseases
  • Peripheral Artery Diseases

By End User

  • Hospitals
  • Cardiac Centers

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Competitive Landscape in Bioresorbable Stent Market:

  • Abbott
  • REVA Medical, Inc.
  • Elixir Medical Corporation
  • Kyoto Medical Planning Co., Ltd.
  • Biotronik
  • Amaranth Medical, Inc.
  • Arterial Remodeling Technologies
  • Meril Life Sciences Pvt. Ltd.
  • Arterius Limited
  • Boston Scientific Corporation

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=4246&license=multi

**Objectives of this Study: **

  1. To provide a comprehensive analysis of the Bioresorbable Stent Market By Material, By Absorption Rate, By Application, By End User and By Region.
  2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
  3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
  4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

                                                                                                                

Flexible Delivery Model:

  • We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
  • The customization services offered are free of charge with the purchase of any license of the report.
  • You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com